Publication | Open Access

Plasma concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 study

Hematological MalignancyChronic Myeloid LeukemiaOncologyDasatinib Dose ReductionHematologyDaria 01Myeloid NeoplasiaMedicineRadiation OncologyCancer ResearchHealth Sciences